eyepoint logo.png
EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments
March 05, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
– Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of...
eyepoint logo.png
EyePoint Announces Participation at Upcoming Investor Conferences
March 04, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
eyepoint logo.png
EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
February 26, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
eyepoint logo.png
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference
February 25, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
– Company presentation scheduled on Tuesday, March 4th at 9:10am ET – – EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup...
eyepoint logo.png
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 17, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
eyepoint logo.png
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
February 05, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and...
eyepoint logo.png
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
January 30, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...
eyepoint logo.png
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 16, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
eyepoint logo.png
EyePoint Provides Company Update and Anticipated Development Milestones for 2025
January 13, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2...
eyepoint logo.png
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors
January 08, 2025 07:00 ET | EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives...